BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22155829)

  • 1. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
    Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
    Carvajal SK; Melendres J; Escandón P; Firacative C
    Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
    Bosco-Borgeat ME; Mazza M; Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G
    Rev Argent Microbiol; 2016; 48(2):137-42. PubMed ID: 27311753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis.
    Kano R; Okubo M; Yanai T; Hasegawa A; Kamata H
    Mycopathologia; 2015 Dec; 180(5-6):427-33. PubMed ID: 26162642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
    Gast CE; Basso LR; Bruzual I; Wong B
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole.
    Kano R; Okubo M; Hasegawa A; Kamata H
    Med Mycol; 2017 Nov; 55(8):877-882. PubMed ID: 28927230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.
    Flowers SA; Colón B; Whaley SG; Schuler MA; Rogers PD
    Antimicrob Agents Chemother; 2015 Jan; 59(1):450-60. PubMed ID: 25385095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning of the lanosterol 14-α-demethylase ( ERG11 ) gene in Trichosporon asahii: a possible association between G453R amino acid substitution and azole resistance in T. asahii.
    Kushima H; Tokimatsu I; Ishii H; Kawano R; Shirai R; Kishi K; Hiramatsu K; Kadota J
    FEMS Yeast Res; 2012 Sep; 12(6):662-7. PubMed ID: 22621704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.
    Hull CM; Parker JE; Bader O; Weig M; Gross U; Warrilow AG; Kelly DE; Kelly SL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4223-32. PubMed ID: 22615281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
    Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14α-Demethylase.
    Sagatova AA; Keniya MV; Tyndall JDA; Monk BC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
    Sionov E; Chang YC; Garraffo HM; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2804-15. PubMed ID: 19414582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.
    Rodero L; Mellado E; Rodriguez AC; Salve A; Guelfand L; Cahn P; Cuenca-Estrella M; Davel G; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3653-6. PubMed ID: 14576140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature.
    Morio F; Loge C; Besse B; Hennequin C; Le Pape P
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):373-84. PubMed ID: 20226328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of the Direct Contribution of Candida auris
    Rybak JM; Sharma C; Doorley LA; Barker KS; Palmer GE; Rogers PD
    Microbiol Spectr; 2021 Dec; 9(3):e0158521. PubMed ID: 34878305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.